Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Director Sells 8,346 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Chris Anigeron Rallis sold 8,346 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of C$9.67, for a total transaction of C$80,705.82. Following the transaction, the director directly owned 61,314 shares in the company, valued at C$592,906.38. This trade represents a 11.98% decrease in their ownership of the stock.

Chris Anigeron Rallis also recently made the following trade(s):

• On Monday, May 11th, Chris Anigeron Rallis purchased 14,344 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average cost of C$3.35 per share, for a total transaction of C$48,052.40.

Fennec Pharmaceuticals Price Performance

Shares of FRX stock remained flat at C$9.65 during trading hours on Monday. 101 shares of the company’s stock traded hands, compared to its average volume of 1,106. The stock has a market capitalization of C$334.98 million, a P/E ratio of -28.38 and a beta of 3.22. Fennec Pharmaceuticals Inc. has a 52-week low of C$7.59 and a 52-week high of C$13.83. The stock has a 50-day simple moving average of C$9.50 and a 200 day simple moving average of C$10.46.

Analyst Ratings Changes

Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Strong Buy”.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.